ASTCT™ and CIBMTR® 2023

Wednesday, February 15, 2023
 

S-P1 - Plenary [ASTCT/CIBMTR/EBMT Joint Plenary]: Lessons from the Pandemic: Are We Stronger?

Chair: Brenda Sandmaier, M.D.
Wednesday, Feb 15, 9:00-10:30 a.m. (ET)

Accelerated Aging: Elderly Children after Hematopoietic Cell Transplantation

Presenter: K. Scott Baker, M.D., M.S.
Wednesday, Feb 15, 11:30-12:00 p.m. (ET)

Global Data on HSCT for Acute Myeloid Leukemia

Presenter: Molly Tokaz, M.D.
Wednesday, Feb 15, 12:00-12:30 p.m. (ET)

Acute Vs. Chronic Gvhd Presentation & Treatment Algorithm

Presenter: Masumi Ueda Oshima, M.D., M.A.
Wednesday, Feb 15, 12:45-1:15 p.m. (ET)

The Scope and Management of cGvHD Treatment Related Complications on Growth and Development in the Pediatric/Adolescents

Presenter: Paul Carpenter, MB.BS.
Wednesday, Feb 15, 1:15-1:30 p.m. (ET)

19 - A Double-Blind Placebo-Controlled Trial of Fecal Microbiota Transplantation in Allogeneic Hematopoietic Cell Transplantation Recipients

Presenter: Armin Rashidi, M.D., Ph.D.
Wednesday, Feb 15, 3:00-3:15 p.m. (ET)

15 - Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study

Presenter: Nicholas Gazeau
Wednesday, Feb 15, 3:30-3:45 p.m. (ET)

9 - Subgroup Analyses of Kte-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Adult Patients (Pts) with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) in Zuma-3

Corresponding Author: Ryan Cassaday, M.D.
Wednesday, Feb 15, 3:30-3:45 p.m. (ET)

T-Cell Depletion: Emerging Strategies

Presenter: Marie Bleakley, M.D., Ph.D., M.MSC.
Wednesday, Feb 15, 4:45-5:15 p.m. (ET)

S-P3 - Plenary [ASTCT]: Novel Antibody-Based Conditioning Regimens

Chair: Brenda Sandmaier, M.D.
Thursday, Feb 16, 8:45-10:15 a.m. (ET)

Present and Future of Radioimmunotherapy for Hematopoietic Cell Transplantation

Presenter: Roland Walter, M.D., Ph.D., M.S.
Thursday, Feb 16, 9:15-9:45 a.m. (ET)

Dying to Regenerate: Harnessing Mechanisms of Endogenous Thymic Regeneration to Enhance Immune Reconstitution

Presenter: Jarrod Dudakov, Ph.D.
Thursday, Feb 16, 11:45-12:15 p.m. (ET)

36 - Final Safety and Efficacy Results from Equate, an Open-Label Study Evaluating Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease

Corresponding Author: Marco Mielcarek, M.D.
Thursday, Feb 16, 3:45-4:00 p.m. (ET)

114 - Excellent Progress in Overall Transplant Outcomes for Patients with Fanconi Anemia Including Adult FA Patients and Those with Myelodysplastic Syndrome Using Risk Adjusted Cytoreduction without Radiation.

Corresponding Author: K. Scott Baker, M.D., M.S.
Thursday, Feb 16, 4:45-5:00 p.m. (ET)

333 - Decline in Chronic Gvhd (cGVHD) at Fred Hutchinson Cancer Center between 2005 and 2019

Presenter: Paul Carpenter, MB.BS.
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

169 - Outcomes for Pediatric Myeloid Malignancy Patients Requiring Pediatric Intensive Care Unit (ICU) Admission Post-HCT

Corresponding Author: Ted Gooley, Ph.D., Heather Persinger, M.A., Ann Dahlberg, M.D., Brandon K. Hadland, M.D., Ph.D., Scott Nicholas Furlan, M.D., Monica S. Thakar, M.D., Marie Bleakley, M.D., Ph.D., M.MSC., Corinne Summers, M.D. 
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

129 - Bronchiolitis Obliterans Syndrome in Myelofibrosis Patients Post-Allogeneic Hematopoietic Cell Transplantation

Corresponding Author: Rachel B. Salit, M.D.
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

306 - Fresh Versus Cryopreserved Allograft Outcomes in Peripheral Blood Stem Cell Transplantations

Presenter: Laura Roberts
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

408 - HLA Evolutionary Divergence Does Not Predict Relapse and Survival Following Allogeneic Hematopoietic Stem Cell Transplant for Myeloid and Lymphoid Malignancies

Corresponding Author: Stephanie Lee, M.D., MPH
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

458 - Demographics, Motivations, and Experiences of Participants in Transplantation or Cellular Therapy Fellowships

Presenter: Rahul Banerjee, M.D., F.A.C.P.
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

500 - 3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Corresponding Author: David G. Maloney, M.D., Ph.D.
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

559 - Revisiting the Role of Post-Transplant Central Nervous System Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Presenter: Neel S. Bhatt, M.B.B.S., MPH
Wednesday, Feb 16, 5:45-6:45 p.m. (ET)

599 - Role of Clinical Trial Coordinator RN within Immunotherapy Clinic

Presenter: Soyoung Park, M.D.
Thursday, Feb 16, 5:45-6:45 p.m. (ET)

Futility in Cancer Care and Treatment

Presenter: Jodie M. David
Friday, Feb 17, 8:45-10:00 a.m. (ET)

Welcome/Panel Q&A

Presenter: Mary Flowers, M.D.
Friday, Feb 17, 8:45-10:00 a.m. (ET)

Trust Your Gut: Microbiome

Presenter: Armin Rashidi, M.D., Ph.D.
Friday, Feb 17, 1:15-1:35 p.m. (ET)

S-C9 - Concurrent: How CAR-Ts Drive the Cell Therapy Treatment Landscape for Lymphoma Patients Chair

Presenter: Mazyar Shadman, M.D., MPH
Friday, Feb 17, 2:00-3:30 p.m. (ET)

56 - Impact of Rabbit Anti-Thymocyte Globulin (rATG) Exposure in Ex Vivo T-Cell Depleted Hematopoietic Cell Transplantation in Children and Young Adults

Presenter: Madhavi Lakkaraja, M.D., MPH
Friday, Feb 17, 4:00-4:15 p.m. (ET)

120 - Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy

Presenter: Ivan Huang, PharmD
Friday, Feb 17, 4:30-4:45 p.m. (ET)

Best Practice Panel: Vaccinations in HCT and Cellular Therapy Patients

Presenter: Alycia Hatashima
Saturday, Feb 18, 9:10-9:35 a.m. (ET)

Targeting WT1 with T-Cell Receptor Gene Therapy

Presenter: Aude Chapuis, M.D.
Saturday, Feb 18, 3:15-3:45 p.m. (ET)

ASTCT Lifetime Achievement Award

Presenter: Frederick Appelbaum, M.D.
Saturday, Feb 18, 6:15-6:45 p.m. (ET)